Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: St. Jude/Cyberonics

This article was originally published in The Gray Sheet

Executive Summary

St. Jude/Cyberonics: Merger agreement cleared by Cyberonics shareholders, the firm announces July 23. The action gives St. Jude until October 18 to exercise its option to complete a $72 mil. merger transaction under an April 8 agreement -- time to evaluate results from a second clinical trial of Cyberonics' NCP (NeuroCybernetic Prosthesis) neurological stimulation device ("The Gray Sheet" April 15, I&W-3). Cyberonics also completes the sale of 2.2 mil. new shares of common stock to St. Jude at $5.50 each for an aggregate of $12 mil. -- the merger agreement called for the equity financing upon Cyberonics shareholder approval...

You may also be interested in...

Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal

As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.

C-Suite Snippets: Growth Of A Cell And Gene Powerhouse

In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.

UK-US GCP Collaboration Going Strong But Mutual Recognition Not Feasible

While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts